(Hepatocellular Carcinoma) Imfinzi + Tremelimumab Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On May 29-31, 2020, Robin Kate Kelley presented at ASCO 2020 virtual conference: "Efficacy and safety results of anti-PD-L1 antibody Imfinzi (durvalumab) + anti-CTLA-4 antibody Tremelimumab in treatment-naive advanced hepatocellular carcinoma patients who have not used immune checkpoint inhibitors in Phase 2 clinical trial."
This Phase 2 clinical trial divided treatment-naive advanced hepatocellular carcinoma patients who have not used immune checkpoint inhibitors into four groups with primary endpoint safety and secondary endpoints overall survival, objective response rate, and duration of response:
- D + T300 group (4-week cycle, Imfinzi 1500mg + Tremelimumab 300mg, N=75 patients).
- D + T75 group (4-week cycle, Imfinzi 1500mg + Tremelimumab 75mg, N=84 patients).
- D group (4-week cycle, Imfinzi 1500mg, N=104 patients).
- T group (4-week cycle, Tremelimumab 750mg, N=69 patients).
In this trial, Grade 3-4 adverse event rates were: D + T300 group 35.1% / D + T75 group 24.4% / D group 17.8% / T group 42.0%. Treatment discontinuation rates due to adverse events: D + T300 group 10.8% / D + T75 group 6.1% / D group 7.9% / T group 11.6%.
Secondary endpoint median overall survival: D + T300 group 18.7 months / D + T75 group 11.3 months / D group 11.7 months / T group 17.1 months. Objective response rates: D + T300 group 22.7% / D + T75 group 9.5% / D group 9.6% / T group 7.2%. Median duration of response: D + T300 group not reached / D + T75 group 13.2 months / D group 14.8 months / T group 24.0 months.
Based on Phase 2 clinical trial results, Robin Kate Kelley concluded: Treatment-naive advanced hepatocellular carcinoma patients treated with anti-PD-L1 antibody Imfinzi + anti-CTLA-4 antibody Tremelimumab 300mg showed better anti-tumor efficacy compared to other groups, with manageable adverse events.
Note: The clinical trial data and medical information translated by "Medical Assistant" from overseas trials are not intended to promote participation in clinical trials or use of new drugs. Translation materials are for reference only, not as medication guidelines. Please consult healthcare professionals and refer to original content for accuracy.
Source: Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020 ASCO Virtual Scientific Program, Abstract No:4508)
-
Immunotherapy
-
Clinical Trial Drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase 2 Trial Results. (Lung Cancer) Non-Small Cell Lung Cancer with HER2 Gene Mutation: Effective with Enhertu? (Lung Cancer) Anti-B7-H3 Antibody DS-7300 Effective?
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4